Amneal Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
AMRX
CUSIP
03168L105
All holders as of
Q2 2026
Type
Equity
Class
COM STK CL A
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 03168L105 since 12/18/2024, newest first.

Filer % of Class Filed
Patel Tushar Bhikhubhai 13D/A Amendment 6 17.6% 8/12/2026
Event 8/10/2026
Patel Chirag K. 13D/A Amendment 7 8.4% 8/12/2026
Event 8/10/2026
Chintu Patel 13D/A Amendment 5 9.4% 8/12/2026
Event 8/10/2026
BlackRock, Inc. 13G 7.6% 4/27/2026
Event 3/31/2026
Patel Dipan 13D/A Amendment 5 5.4% 3/26/2026
Event 12/31/2025
Vanguard Group Inc 13G/A Amendment 1 0% 3/26/2026
Event 3/13/2026
Patel Chintu 13D/A Amendment 4 8.2% 10/7/2025
Event 10/3/2025
Patel Dipan 13D/A Amendment 4 7.6% 10/6/2025
Event 10/3/2025
Patel Chirag K. 13D/A Amendment 6 7.1% 8/8/2025
Event 8/6/2025
Akram Mahesh 13G/A Amendment 2 6.6% 5/14/2025
Event 3/31/2025
Vanguard Group Inc 13G 5.0% 4/30/2025
Event 3/31/2025
Patel Tushar Bhikhubhai 13D/A Amendment 5 15.7% 3/17/2025
Event 3/14/2025
UBS Group AG 13G/A Amendment 1
Checked 5% or less
2/10/2025
Event 12/31/2024
Patel Dipan 13D/A Amendment 3 7.7% 1/23/2025
Event 11/13/2024
UBS Group AG 13G 6.9% 10/30/2024
Event 9/30/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 43 4.59 M $91.4 M
2026 Q2 319 172 M $3.11 B
2026 Q1 322 161 M $2.00 B
2025 Q4 285 155 M $1.95 B
2025 Q3 253 152 M $1.52 B
2025 Q2 248 145 M $1.18 B
2025 Q1 246 136 M $1.14 B
2024 Q4 211 126 M $999 M
2024 Q3 190 144 M $1.20 B
2024 Q2 191 143 M $900 M
2024 Q1 185 110 M $665 M
2023 Q4 162 113 M $685 M
2023 Q3 151 102 M $431 M
2023 Q2 134 97.5 M $302 M
2023 Q1 152 97.3 M $135 M
2022 Q4 165 104 M $209 M
2022 Q3 162 99.7 M $203 M
2022 Q2 157 99.4 M $316 M
2022 Q1 176 100 M $417 M
2021 Q4 165 101 M $482 M
2021 Q3 161 100 M $535 M
2021 Q2 166 99.9 M $512 M
2021 Q1 168 102 M $684 M
2020 Q4 144 100 M $457 M
2020 Q3 148 102 M $394 M
2020 Q2 146 102 M $484 M
2020 Q1 135 98.4 M $342 M
2019 Q4 136 103 M $495 M
2019 Q3 129 125 M $362 M
2019 Q2 143 106 M $757 M
2019 Q1 173 110 M $1.55 B
2018 Q4 174 117 M $1.58 B
2018 Q3 178 111 M $2.47 B
2018 Q2 170 97.6 M $1.60 B